AeroForm Named Gold Winner and Best in Show of the 2018 Medical Design Excellence Awards
SAN JOSE, Calif. (PRWEB) July 24, 2018 -- AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company) today announced that the AeroForm Tissue Expander System has been named a Gold Winner and Best in Show at the 2018 Medical Design Excellence Awards (MDEA). The awards recognize AeroForm as the highest rated product of the show for its significant achievement in medical product design and for improving the quality of healthcare delivery.
"We're honored that MDEA recognized our excellence in engineering and commitment to providing breast cancer patients and their surgeons with an innovative medical technology," said Frank Grillo, President & CEO, AirXpanders. "Our breakthrough AeroForm technology is the first major advancement in tissue expansion for breast reconstruction in 50 years. We offer women a patient-controlled approach to tissue expansion that affords more comfort and convenience than traditional methods."
The AeroForm Tissue Expander System offers a needle-free alternative for women who choose reconstructive surgery with implants following a mastectomy. Developed by a plastic surgeon and inspired by a carbon dioxide bicycle pump canister, the AeroForm Tissue Expander is surgically inserted either underneath or above the chest muscle. It is activated by a handheld wireless controller that triggers a valve to release small amounts of carbon dioxide (CO2), up to three times a day, to gradually stretch the tissue and prepare for insertion of a breast implant. With the push of a button from the wireless controller, a pre-programmed amount of CO2 is delivered in seconds, allowing women to continue with their daily activities while preparing for reconstruction.
Jeffrey Ascherman, M.D., Columbia University Medical Center, added, "This is a wonderful and well-deserved recognition for the AeroForm Tissue Expander System. The traditional saline expanders that have been used for decades can involve painful needle injections and frequent visits to the doctor’s office that may add stress to the process. As an alternative, the AeroForm Tissue Expander System allows patients to expand from their own home. The device is a major advancement, and gives women control over a process that previously often felt uncontrollable. My AeroForm patients have been so happy to use the device, and their overall experiences and outcomes have been terrific."
The Medical Design Excellence Awards (MDEA) is the premier awards program for the medtech industry. Since its inception in 1998, the mission of the MDEAs has been to recognize significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility. The awards program celebrates the achievements of the medical device manufacturers, their suppliers, and the many people behind the scenes—engineers, scientists, designers, and clinicians—who are responsible for the cutting-edge products that are saving lives; improving patient healthcare; and transforming medtech—one innovation at a time.
Company
Frank Grillo
President & CEO
1 (650) 390 9000
Email: fgrillo(at)airxpanders.com
Investor Relations
Kyahn Williamson
WE Buchan
Tel: +61 (3) 9866 4722 / +61 (0)401 018 828
Email: kwilliamson(at)we-buchan.com
About AirXpanders
Founded in 2005, AirXpanders, Inc. designs, manufactures and markets innovative medical devices to improve breast reconstruction. The AeroForm Tissue Expander System is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in San Jose, California, AirXpanders’ vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction. AirXpanders is a publicly listed Company on the Australian Securities Exchange under the symbol “AXP.” AeroForm received its first CE mark in Europe in 2012, TGA clearance for commercialization in Australia in 2013; it was granted U.S. FDA de novo marketing authorization in 2016, and subsequent U.S. market 510k clearance in 2017. For more information, refer to the Company's website at http://www.airxpanders.com
Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.
All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, the benefits of AeroForm as compared to saline tissue expanders and to patients and doctors.
Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements. For additional information and considerations regarding the risks faced by AirXpanders that could cause actual results to differ materially, see its most recent Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on May 3, 2018, including under the caption "Risk Factors," as well as other periodic reports filed with the SEC. AirXpanders disclaims any obligation to update information contained in any forward-looking statement, except as required by law.
Karen Serpa, Health & Commerce, +1 415-676-1923, [email protected]
Share this article